BISPHOSPHONATE RELATED OSTEONECROSIS OF THE JAW (BRONJ)

Slides:



Advertisements
Similar presentations
The Female Athlete Triad Keren Kazis, M.D. Adolescent Medicine Department of Pediatrics New York Medical College.
Advertisements

Implementing NICE guidance ABOUT THIS PRESENTATION:
Shafiepour,mohsen MD. Kerman university of medical sciences.
Osteoporosis 9 th January 2013 Dr Julian Tomkinson.
OSTEOPOROSIS An overview of the condition and its treatment
Osteoporosis Metabolic Bone Disease. Osteoporosis Characterized by low bone mass and structural deterioration Normal homeostatic bone remodeling is altered.
Osteoporosis Dr. Aisha Sheikh FCPS (Pak), Fellowship Diabetes/Endocrinology (AKUH), PG Dip Diab (UK) Consultant Endocrinologist.
Prevent Osteoporosis… GET “BONE” HEALTHY KENTUCKY.
DISORDERS OF MAXILLA AND MANDIBLE
WHO Osteoporosis Definition (1996)
Aging of the Skeleton: Osteoporosis An Evolutionary and Biocultural Perspective.
King Abdul Aziz University Faculty Of Pharmacy
The Scope of Musculoskeletal Disease Treatment and Costs Prof Stephen Graves University of Melbourne.
Postoperative Radiation for Oral Cavity Squamous Cell Carcinoma: The EP.
Dr santosh kumar Assistant professor Medical unit 2.
Osteoporosis Dr. Lauren Phillips Sugar Land Women’s Health.
Bone Mineral Density Testing March 29, Introduction Osteoporosis is a systemic skeletal disorder characterized by decreased bone mass and deterioration.
Osteoporosis Osteoporosis is defined as a loss of bone mass or bone mineral density characterized by height reduction, fractures, back/neck pain, and stooped.
Treatment. Bisphosphonates Promotes bone formation and decreases bone resorption Mechanism of Action First line treatment for osteoporosis in both men.
Osteoporosis Rajesh Kataria, D.O. Southern Ohio Rheumatology.
Osteoporosis. Introduction Osteoporosis is “a disease of the bones that happens when you lose too much bone, make too little bone, or both.” - National.
Osteoporosis Rajesh Kataria, D.O.. Osteoporosis “…is a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of.
OSTEOPOROSIS Prof. Dr. Ülkü Akarırmak. Metabolic Bone Diseases Osteosclerosis Osteolysis Osteoporosis is the most common metabolic bone disease.
OSTEOPOROSIS 06/25/12 José L. González, PGY3. Definition  Reduction in bone strength  increase risk of fx  T-score: < -2.5 SDs  T-score: 30 yo, matched.
1Stopeck A et al. Proc SABCS 2010;Abstract P
PREVENTION IS THE BEST STRATEGY, THE SAME AS FOR ANY OTHER ILLNESS (IF YOU RECOGNIZE IT, YOU AVOID IT)
Mosby items and derived items © 2007 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 21 Antineoplastic Drugs.
joints Prepared by Dr.Salah Mohammad Fateh MBChB,DMRD,FIBMS(radiology)
SKELETAL SYSTEM. Diseases/Disorders Sprain – stretched or torn ligament or tendon Arthritis – inflamed joint Osteomyelitis – infected bone Osteoporosis.
Hanna Przepiera-Będzak Klinika Reumatologii PAM, Szczecin.
Denosumab NICE technology appraisal guidance 204 October 2010.
Update journal reading 指導老師 : 陳玉昆醫師 報告者 : R2 林雁秋.
1 Tuesday 28 Oct 2008 Hall I Session I: 8:00- 10:00 Symposium... 1 Tuesday 28 Oct 2008 Hall I Session I: 8:00- 10:00 Symposium...
Glucocorticoid-Induced Osteoporosis (GIO) Nguyen Thy Khue, MD, PhD Department of Endocrinology, HoChiMinh City University of Medicine and Pharmacy.
Own the Bone Pilot Project Created February 2007
MANAGEMENT OF OSTEOPOROSIS Professor Opinder Sahota Consultant Physician QMC, Nottingham.
Vietnam Osteoporosis Workshop, HCM Cty 2006 OSTEOPOROSIS IN MEN Tuan Van Nguyen and Nguyen Dinh Nguyen Garvan Institute of Medical Research Sydney, Australia.
Osteoporosis. What is Osteoporosis? A person with osteoporosis has lost a significant amount of bone mass and is subsequently at increased risk for fracture.
Physical Activity & Bone Health. Bone Density The amount of mineral matter in bone increases from birth until 35 to 45 years old. Generally, females have.
American Association of Oral and Maxillofacial Surgeons Osteonecrosis Guidelines Biochemical and molecular mechanisms of action of bisphosphonates Michael.
Bisphosphonates effectively manage bone complications from cancer
Osteoporosis Armed Forces Academy of Medical Sciences.
Core Benefit/Risk (CR)
Osteoporosis. Background ► The problem  Osteoporosis is common  Over 50% of women and 30-45% of men over age 50 have osteopenia/osteoporosis  White.
Osteoporosis: Measuring the Problem
Osteoporosis Dr Ramin Rafiei Alzahra Hospital Rheumatology Department.
Cancer, Exercise & Bone Health
Prevention and Treatment of Osteoporosis
Osteonecrosis of the Jaws in Myeloma BRIAN G.M. DURIE, M.D., Michael Katz, Jason McCoy, MS and John Crowley, PhD Hematology/Oncology, Cedars-Sinai Outpatient.
REGULATORY HISTORY of ZOMETA and AREDIA JAW OSTEONECROSIS (ONJ) Oncologic Drug Advisory Committee March 4, 2005 Nancy S. Scher, M.D.
Osteoporosis In Thalassemia Dr Tarek Jawad INT 555.
Welcome To Our Presentation
OSTEOPOROSIS. Characteristics of osteoporosis include a reduction of bone density and a change in bone structure, both of which increase susceptibility.
Bone Health Secondary Breast Cancer
Rheumatology Normal Anatomy andPhysiology. Synovial joints: Normal Anatomy 1. Bone: 2. Cartilage: 3. Synovium:
Osteoporosis Vinod Kurup, MD December 22nd, 2006 CC-BY-SA.
Bone Health & Nutrients Chapter 11 – HLTH 120N. What do you know about your bones?  What is peak bone density?  At about what age do you reach it? 
Osteoporosis. Background Osteoporosis is disorders of the bone, characterized by progressive loss of bone mass and skeletal fragility. Patients with osteoporosis.
Osteoporosis.
Endocrine Disorders Parathyroid Gland
Dr Sarah Constantine MBBS, FRANZCR
Clinical staging of DrugRelated OsteoNecrosis of the Jaws: a new proposal Celentano A, Sadile G, Leuci S, Adamo D, Sammartino G, Mignogna MD, Ruoppo E.
Osteoporosis هشاشة العظام Dr.Fakhir Yousif.
Buy Fosamax - Get Relief from Bone Disease
Post Menopausal Osteoporosis
STOHN BONJ Process development
Chapter Drugs used for the treatment of osteoporosis
(Relates to Chapter 64, “Focous on osteoperosis ,” in the textbook)
Presentation transcript:

BISPHOSPHONATE RELATED OSTEONECROSIS OF THE JAW (BRONJ)

BISPHOSPHONATES AND WHAT HAPPENS TO BONE VINCENT E. DIFABIO, DDS, MS MEMBER OF THE COMMITTEE ON HEALTHCARE AND ADVOCACY FROM THE AMERICAN ASSOCIATION OF ORAL & MAXILLOFACIAL SURGERY (AAOMS) ASSOCIATE PROFESSOR OF ORAL & MAXILLOFACIAL SURGERY UNIVERSITY OF MARYLAND, BALTIMORE, MARYLAND AND PRIVATE PRACTICE OF ORAL & MAXILLOFACIAL SURGERY, FREDERICK, MARYLAND

BISPHOSPHONATES AND WHAT HAPPENS TO BONE PRESENT THE POTENTIAL FOR A DIFFERENT ETIOLOGY OF BONE DESTRUCTION IN THE MAXILLA AND MANDIBLE AND THE NEED FOR SPECIFIC CODES TO REPRESENT THIS DIFFERENT ETIOLOGY OF BONE DESTRUCTION SEEN IN THE MAXILLA AND MANDIBLE

OSTEONECROSIS OF THE JAW NOT A NEW DISEASE OR PHENOMENON “PHOSSY JAW” DATES BACK TO THE 19TH CENTURY RELATED TO MATCHSTICK MAKING HIGH LEVELS OF PHOSPHORUS

BISPHOSPHONATES ARE USED TO TREAT SEVERAL DISEASE ENTITIES OSTEOPOROSIS CANCER PATIENTS RECENT PAPERS HAVE SHOWN THAT A JAW OSTEONECROSIS OF ASEPTIC ETIOLOGY IS ASSOCIATED WITH THE USE OF BISPHOSPHONATES

OSTEOPOROSIS TREATED WITH BISPHOSPHONATES (BPs) MANY PEOPLE WORLD WIDE ARE RECEIVING THESE TYPES OF MEDICATIONS IS THIS TREATMENT OF OSTEOPOROSIS WITH BPs OF CONCERN???

Osteoporosis Primary disease: quantities of sex hormones Phase 1: trabecular bone resorption due to estrogen deficiency. Peaks after 4-8 years (women only) Phase 2: persistent, slower loss of both trabecular and cortical bone which is mainly due to decreased bone formation (men and women)

Osteoporosis Secondary disease: consequence of other diseases or medications Long term steroid use, Cushing’s disease, anorexia nervosa, athletic amenorrhea, HPT, cystic fibrosis, inflammatory bowel disease, rheumatoid arthritis Observed in young/old, men/women Osteoporosis ICD-9-CM Codes: 733.0 – 733.09

Osteoporosis Unbalanced bone remodeling where bone formation = bone resorption Defined as a disease with low bone mass and deterioration of bone structure resulting in bone fragility and increase risk of fracture Females >>>Males Primary vs. Secondary Lerner AH, J. Dent Res 85. 2006

Osteoporosis is a BIG problem in the USA! Surgeon General Report (2004) 40% of American women > 50 yo. Will experience an osteoporotic fracture 13% of men 50 yo. By 2020 it is estimated that 50% of all Americans over the age of 50 will be at risk of developing osteoporosis Direct cost expenditures for 1.3 million fx per yr = $14 billion +

OSTEOPOROSIS THE BIG QUESTION IS WILL THESE PATIENTS IN THE FUTURE DEVELOP A SIMILAR OSTEONECROSIS OF THE JAW???

OSTEORADIONECROSIS NOTED WITH THE INTRODUCTION OF RADIATION THERAPY TO TUMORS OF THE HEAD AND NECK RADIATION CREATES HARD AND SOFT TISSUE HYPOXIA, HYPO-CELLULARITY AND HYPO-VASCULARITY RESULTS IN A SIGNIFICANT DECREASE IN HEALING AND NECROSIS OF BONE OSTEORADIONECROSIS OF THE JAWS ICD - 9- CM CODE: 526.89

OSTEOMYELITIS BACTERIAL INFECTION OF THE BONE PRIMARY OR SECONDARY TO DENTAL OR OTHER ORAL INFECTIONS OSTEOMYELITIS OF THE BONE: 730 – 730.9 INCLUDES ACUTE AND CHRONIC and OSTEOMYELITIS OF THE JAW: 526.4 and 526.5

PATHOPHYSIOLOGY ALTHOUGH THE OSTEORADIONECROSIS (RADIATION INDUCED), OSTEOMYELITIS (BACTERIAL INFECTION) AND BISPHOSPHONATE RELATED OSTEONECROSIS OF THE JAW (ASEPTIC NECROSIS & DRUG INDUCED) ARE DIFFERENT IN ETIOLOGY, THEY ARE SIMILAR IN PATHOLOGY AND SECONDARY INFECTIONS AND WILL THE OSTEOPOROSIS PATIENTS TREATED WITH BPs DEVELOP A SIMILAR ONJ IN THE FUTURE??

ICD-9-CM WE HAVE SPECIFIC ICD-9-CM CODES FOR OSTEOPOROSIS, OSTEOMYELITIS AND OSTEORADIONECROSIS SO WHY NOT USE THESE CODES FOR BP RELATED ASEPTIC OSTEONECROSIS OF THE JAW OR BRON JAW??

NEED FOR A SPECIFIC CODE REPORTING INCIDENCE OF OCCURRENCE AND TRACKING RESEARCH EVALUATION & MANAGEMENT AND SURGICAL PROCEDURES OF MAXILLA AND MANDIBLE LINKED TO A SPECIFIC VS NON-SPECIFIC ICD-9CM CODE

BISPHOSPHONATE RELATED OSTEONECROSIS OF THE JAW (ONJ) FIRST RECOGNIZED IN 2003 AS A COMPLICATION OF BISPHOSPHONATE THERAPY HIGHER FREQUENCY IN THE MANDIBLE (63%) THAN IN THE MAXILLA (38%) ETIOLOGY IS UNCLEAR AND IS THE SUBJECT OF CURRENT RESEARCH AND INVESTIGATION

BRONJ CAN BE RELATED TO DENTAL TREATMENT CAN BE RELATED TO DENTAL PATHOLOGY CAN BE SPONTANEOUS WITH DENTAL ETIOLOGY CAN BE RELATED TO DENTURE IRRITATION OR WEAR CAN BE UNRELATED TO ANY OF THE ABOVE CAN BE RELATED TO LOCAL TRAUMA CAN BE UNKNOWN IN ETIOLOGY

PROPOSED INDUCTION MECHANISMS INHIBITION OF OSTEOCLAST ACTIVITY REDUCES BONE TURNOVER REDUCING REMODELING DECREASED NEW BONE FORMATION ETIOLOGY IS UNKNOWN BUT IS LIKELY MULTIFACTORIAL

BRONJ TRUE INCIDENCE IS DIFFICULT TO ESTIMATE DEPENDING ON RECENT RETROSPECTIVE REPORTS COULD BE <1%-9% OF CANCER PATIENTS RECEIVING BISPHOSPHONATES SEEN IN CANCER PATIENTS WITH MULTIPLE ANTINEOPLASTIC MEDICATIONS AS WELL AS BISPHOSPHONATES MULTIPLE MYELOMA, BREAST CANCER AND PROSTATE CANCER ARE THE PRIMARY NEOPLASMS AFFECTED AND WHAT ABOUT OSTEOPOROSIS PATIENTS TREATED WITH BPs?????

ONJ MULTIPLE PAPERS RELATING BPs WITH ONJ SINCE 2003 RELATED TO METHOD OF ADMINISTRATION OF BPs: IV VS PO RELATED TO THE DURATION OF ADMINISTRATION VERY SERIOUS SEQUELAE WHEN ONJ DEVELOPS

BP’s Mechanism of action 1) Tissue level a. reduction of bone turnover 2) Cellular level a. inhibition of osteoclastic activity on the bone surface (Rodan et al., Strewler) b. inhibition of osteoclast recruitment on the bone surface (Rodan et al., Vitte et al.) c. osteoclast apoptosis (Hughes et al., Rogers et al.) -The action of BP’s at the molecular level have not been elucidated as of yet -It has been proposed that BP’s interfere with osteoclast intercellular biochemical pathways, either by: Interacting with a cell-surface receptor or… By uptake of the BP by the osteoclast and interference with cellular metabolism -In fact, one study has recently demonstrated that BP’s interact with a receptor on the cell surface of osteoblasts, perhaps interfering with their ability to produce bone as well

BP’s Mechanism of action 3) Molecular level Interferes with osteoclast intercellular biochemical pathways Inhibition of farnesyl diphosphate synthase Metabolized to toxic analogue of ATP (non-nitrogen containing BP’s) -lastly, several in vitro studies have presented evidence that BP’s mediate osteoclast apoptosis at the in vitro Strewler GJ. N Engl J Med 2004;350:1174

Bisphosphonates Pharmacologic action: Pharmacokinetics: - Inhibition of bone resorption Pharmacokinetics: - Distribution: Rapid accumulation in sites of increased bone deposition/resorption, low plasma levels, ½ life of “years” - Metabolism: Not metabolized (nitrogen containing) - Excretion: Renal -Bisphosphonates, such as Aredia, Zometa, and Fosamax, are analogues of pyrophosphates whose primary mode of action is inhibition of bone resorption -These compounds accumulate in sites of increased bone deposition and resorption, where they remain for extended periods of time and are released slowly into the circulation (-low plasma levels for 2 to 28 days)

Staging Stage 1 Characterized by exposed bone that is asymptomatic with no evidence of significant soft tissue infection

Staging Stage 2 Exposed bone associated with pain, soft tissue and/or bone infection

Staging Stage 3 Pathologic fracture Exposed bone associated with soft tissue infection or pain that is not manageable with antibiotics due to the large volume of necrotic bone.

Staging Stage 3 Pathologic fracture Exposed bone associated with soft tissue infection or pain that is not manageable with antibiotics due to the large volume of necrotic bone.

A 40 yo with female with a diagnosis of breast cancer and Zometa therapy (6 months) presents with pain, exposed and infected maxillary bone following extraction

Relative Potency Etidronate (Didronel) 1 Tiludronate (Skelide) 10 Pamidronate (Aredia) 100 Alendronate (Fosamax) 1,000 Risedronate (Actonel) 10,000 Ibandronate (Boniva) 10,000 Zolendronic acid (Zometa) >100,000

PROPOSAL NEW DIAGNOSTIC ICD-9CM CODE FOR THE ASEPTIC NECROSIS OF BONE IN THE JAWS: NEW CODE: 733.45 JAW (MAXILLA AND MANDIBLE) AND APPROPRIATE NEW E CODES TO IDENTIFY THE SPECIFIC ROUTE OF ADMINISTRATION E933.6 ORAL BISPHOSPHONATES AND E933.7 INTRAVENOUS BISPHOSPHONATES

Combinations Use E933.1 antineoplastic & immunosuppressive drugs and May also need to Code for the primary neoplasm (most common ones are prostate, breast and myeloma)